E2F-3 Activators
The chemical class of E2F-3 activators constitutes a diverse array of compounds strategically designed to modulate the activity of E2F-3, a pivotal transcription factor intricately involved in the regulation of the cell cycle. These activators can be broadly classified into two groups: those that directly interact with E2F-3 and those that exert their influence indirectly by targeting key cellular processes. Direct activators within this class encompass Palbociclib, Indirubin, Nutlin-3, Seliciclib, PD-0332991, R547, Roscovitine, NU6027, SCH 900776, LY294002, CAY10572, and GW843682X. Palbociclib and PD-0332991, identified as CDK4/6 inhibitors, indirectly activate E2F-3 by impeding cell cycle progression. This disruption results in the release of E2F-3 and enhances its transcriptional activity. Indirubin, functioning as a CDK inhibitor, disrupts cell cycle progression, impacting Rb phosphorylation, and consequently promotes E2F-3 activation. Nutlin-3, an MDM2 inhibitor, indirectly activates E2F-3 by stabilizing p53, ultimately leading to enhanced E2F-3 transcriptional activity.
The group of CDK inhibitors, including Seliciclib, Roscovitine, NU6027, CAY10572, and GW843682X, influences cell cycle progression by disrupting Rb phosphorylation. This disruption facilitates the release of E2F-3, consequently enhancing its transcriptional activity. R547, a selective inhibitor of Aurora kinase A, impacts mitotic signaling, influencing Rb phosphorylation, and promoting E2F-3 activation. SCH 900776, a CHK1 inhibitor, disrupts the DNA damage response, impacting Rb phosphorylation, and promoting the release of E2F-3. LY294002, a PI3K inhibitor, modulates the PI3K/Akt pathway, influencing Rb phosphorylation and thereby enhancing E2F-3 activity. This diverse array of compounds serves as valuable tools for researchers investigating the intricate regulatory mechanisms governing E2F-3 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Indirubin | 479-41-4 | sc-201531 sc-201531A | 5 mg 25 mg | $114.00 $525.00 | 4 | |
Indirubin, a CDK inhibitor, indirectly activates E2F-3 by modulating cell cycle progression. Inhibition of CDKs disrupts the phosphorylation of Rb, facilitating the release of E2F-3 and enhancing its transcriptional activity. This indirect activation underscores the link between CDK-dependent signaling and E2F-3 function, providing insights into potential modulators of E2F-3 activity through the regulation of CDK activity. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3, a MDM2 inhibitor, indirectly activates E2F-3 by stabilizing p53. Stabilized p53 promotes the transcriptional activation of p21, leading to Rb hypophosphorylation and the release of E2F-3. This indirect activation reveals a connection between the p53 pathway and E2F-3 regulation, suggesting a potential strategy to modulate E2F-3 activity through the inhibition of MDM2. | ||||||
SCH 900776 | 891494-63-6 | sc-364611 sc-364611A | 5 mg 10 mg | $255.00 $338.00 | ||
SCH 900776, a selective inhibitor of CHK1, indirectly activates E2F-3 by influencing cell cycle progression. CHK1 inhibition disrupts the cell cycle checkpoint, impacting Rb phosphorylation and promoting the release of E2F-3. This indirect activation underscores the connection between the DNA damage response and E2F-3 regulation, providing insights into potential modulators of E2F-3 activity through the inhibition of CHK1. | ||||||
PHA 767491 hydrochloride | 942425-68-5 | sc-204187 sc-204187A | 10 mg 50 mg | $198.00 $802.00 | 3 | |
CAY10572, a potent and selective CDK2/5 inhibitor, indirectly activates E2F-3 by influencing cell cycle progression. CDK2/5 inhibition disrupts Rb phosphorylation, facilitating the release of E2F-3 and enhancing its transcriptional activity. This indirect activation highlights the connection between CDK-dependent signaling and E2F-3 function, providing insights into potential modulators of E2F-3 activity through the regulation of CDK2/5. | ||||||
Polo-like Kinase Inhibitor III | 660868-91-7 | sc-203202 | 500 µg | $109.00 | 1 | |
GW843682X, a potent and selective CDK2/9 inhibitor, indirectly activates E2F-3 by influencing cell cycle progression. CDK2/9 inhibition disrupts Rb phosphorylation, facilitating the release of E2F-3 and enhancing its transcriptional activity. This indirect activation emphasizes the connection between CDK-dependent signaling and E2F-3 function, providing insights into potential modulators of E2F-3 activity through the regulation of CDK2/9. | ||||||